Duquesne Family Office LLC Raises Stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Duquesne Family Office LLC boosted its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 65.4% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 14,879,750 shares of the company's stock after buying an additional 5,882,350 shares during the quarter. Teva Pharmaceutical Industries accounts for about 7.5% of Duquesne Family Office LLC's portfolio, making the stock its 2nd largest holding. Duquesne Family Office LLC owned about 1.31% of Teva Pharmaceutical Industries worth $228,702,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Harel Insurance Investments & Financial Services Ltd. raised its stake in shares of Teva Pharmaceutical Industries by 197,885.2% in the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 22,055,547 shares of the company's stock valued at $338,989,000 after acquiring an additional 22,044,407 shares during the period. FMR LLC grew its holdings in shares of Teva Pharmaceutical Industries by 30.7% during the fourth quarter. FMR LLC now owns 81,983,231 shares of the company's stock worth $1,806,910,000 after purchasing an additional 19,242,468 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its stake in Teva Pharmaceutical Industries by 472.8% in the first quarter. Allspring Global Investments Holdings LLC now owns 6,283,688 shares of the company's stock valued at $96,078,000 after buying an additional 5,186,592 shares during the last quarter. Assenagon Asset Management S.A. grew its position in Teva Pharmaceutical Industries by 416.0% during the 1st quarter. Assenagon Asset Management S.A. now owns 5,983,928 shares of the company's stock worth $91,973,000 after purchasing an additional 4,824,247 shares during the last quarter. Finally, Clal Insurance Enterprises Holdings Ltd increased its position in Teva Pharmaceutical Industries by 12.8% in the 4th quarter. Clal Insurance Enterprises Holdings Ltd now owns 38,962,773 shares of the company's stock valued at $859,935,000 after acquiring an additional 4,418,961 shares during the period. 54.05% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms recently weighed in on TEVA. Truist Financial assumed coverage on Teva Pharmaceutical Industries in a research note on Wednesday, May 28th. They issued a "buy" rating and a $25.00 price objective for the company. Hsbc Global Res upgraded shares of Teva Pharmaceutical Industries to a "strong-buy" rating in a report on Monday, April 28th. Bank of America increased their price target on Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the company a "buy" rating in a report on Thursday, May 8th. The Goldman Sachs Group started coverage on Teva Pharmaceutical Industries in a report on Friday, June 6th. They issued a "buy" rating and a $24.00 price target for the company. Finally, JPMorgan Chase & Co. raised Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and raised their price target for the stock from $21.00 to $23.00 in a report on Monday, May 12th. Nine analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Buy" and an average target price of $24.44.

Insider Activity

In other Teva Pharmaceutical Industries news, EVP Matthew Shields sold 6,206 shares of the business's stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $17.02, for a total value of $105,626.12. Following the transaction, the executive vice president now directly owns 9,989 shares in the company, valued at $170,012.78. The trade was a 38.32% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.49% of the company's stock.

Teva Pharmaceutical Industries Stock Performance

NYSE TEVA traded up $0.30 on Thursday, reaching $17.62. The stock had a trading volume of 4,047,158 shares, compared to its average volume of 10,160,100. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75. The firm has a fifty day moving average of $15.90 and a two-hundred day moving average of $17.40. Teva Pharmaceutical Industries Limited has a 1-year low of $12.47 and a 1-year high of $22.80. The company has a market cap of $20.21 billion, a P/E ratio of -12.15, a price-to-earnings-growth ratio of 1.44 and a beta of 0.60.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported $0.52 earnings per share for the quarter, topping the consensus estimate of $0.47 by $0.05. The business had revenue of $3.89 billion during the quarter, compared to the consensus estimate of $3.99 billion. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. Teva Pharmaceutical Industries's revenue for the quarter was up 1.9% on a year-over-year basis. During the same period in the prior year, the company earned $0.48 EPS. On average, equities research analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.